Skip to main content

Nuclear Medicine Areas

The division provides a wide spectrum of nuclear medicine procedures:


  • DaTSCAN for differentiating Parkinsons from other movement disorders
  • PET FDG and amyloid plaque imaging for dementia
  • PET / MRI fusion imaging for tumor and seizure evaluation
  • Custom PET radiopharmaceuticals for research in neurologic and psychiatric studies (C-11 DASB, C-11 Raclopride, C-11 DAA1106, F-DOPA)


  • Thyroid uptake and scans
  • Thyroid cancer imaging (I-131 and I-123) and therapy with radioiodine
  • SPECT pentaoctreotide and PET dotatate imaging for neuroendocrine tumors
  • Parathyroid imaging with SPECT/CT
  • MIBG imaging for pheochromocytoma and neuroblastoma


  • Myocardial perfusion imaging with SPECT/CT
  • Myocardial viability imaging with SPECT and PET
  • MUGA and First pass imaging
  • Cardiac shunt evaluation
  • Myocardial MIBG imaging for sympathetic innervation
  • Myocardial pyrophosphate imaging for detection of amyloidosis


  • V/Q imaging, planar and SPECT, for acute and chronic thromboembolic disease
  • Quantitative V/Q imaging for pre-surgical evaluation


  • emptying and gastroesophageal reflux studies
  • HIDA scans for hepatobiliary function, gallbladder function, sphincter of Oddi, biliary atresia, and biliary leak
  • SPECT imaging for hemangiomas and focal nodular hyperplasia
  • Salivary gland imaging
  • Meckel's scan for detection of gastrointestinal mucosa
  • Acute GI bleeding scan
  • Peritoneal-venous shunt patency (LeVeen, Denver shunts)

Genitourinary Imaging

  • Renal imaging for differential function, hydronephrosis, renovascular hypertension
  • Quantitative measurement of glomerular filtration rate (GFR)
  • Ureteral reflux study
  • Bladder residual volume measurement
  • Testicular flow imaging


  • PET/CT tumor imaging with 18F-fluoro-2-deoxyglucose (FDG)
  • PET/CT bone metastases imaging with 18F-NaF
  • PET/CT imaging with 18F-fluciclovine (Axumin) in prostate cancer
  • PET/CT research with custom PET radiopharmaceuticals (e.g. FLT)
  • SPECT/CT imaging with standard clinical and research radiopharmaceuticals
  • Ra-223 therapy for prostate cancer and research in other cancers
  • Research with new radiopharmaceutical therapies (e.g. Lu-177)
  • Development of new radiopharmaceuticals and applications in tumor and lymph node imaging (e.g. Lymphoseek, FDA approved 3/13/13)